Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • EMT/MET switch
  • Primary and distant tumor microenvironments
  • Suppression of miR-34a is required for IL-6–driven EMT
  • Is MET real in patients?
  • Acknowledgments
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Free access | 10.1172/JCI75239

Microenvironment-dependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch

Julienne L. Carstens, Sara Lovisa, and Raghu Kalluri

Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Raghu Kalluri, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77054, USA. Phone: 713.792.8733; Fax: 713.792.9636; E-mail: rkalluri@mdanderson.org.

Find articles by Carstens, J. in: PubMed | Google Scholar

Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Raghu Kalluri, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77054, USA. Phone: 713.792.8733; Fax: 713.792.9636; E-mail: rkalluri@mdanderson.org.

Find articles by Lovisa, S. in: PubMed | Google Scholar

Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Address correspondence to: Raghu Kalluri, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77054, USA. Phone: 713.792.8733; Fax: 713.792.9636; E-mail: rkalluri@mdanderson.org.

Find articles by Kalluri, R. in: PubMed | Google Scholar

Published March 18, 2014 - More info

Published in Volume 124, Issue 4 on April 1, 2014
J Clin Invest. 2014;124(4):1458–1460. https://doi.org/10.1172/JCI75239.
© 2014 The American Society for Clinical Investigation
Published March 18, 2014 - Version history
View PDF

Related article:

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Matjaz Rokavec, … , Florian R. Greten, Heiko Hermeking
Matjaz Rokavec, … , Florian R. Greten, Heiko Hermeking
Research Article

IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis

  • Text
  • PDF
Abstract

Members of the miR-34 family are induced by the tumor suppressor p53 and are known to inhibit epithelial-to-mesenchymal transition (EMT) and therefore presumably suppress the early phases of metastasis. Here, we determined that exposure of human colorectal cancer (CRC) cells to the cytokine IL-6 activates the oncogenic STAT3 transcription factor, which directly represses the MIR34A gene via a conserved STAT3-binding site in the first intron. Repression of MIR34A was required for IL-6–induced EMT and invasion. Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6–dependent STAT3 activation, as a conserved, direct miR-34a target. The resulting IL-6R/STAT3/miR-34a feedback loop was present in primary colorectal tumors as well as CRC, breast, and prostate cancer cell lines and associated with a mesenchymal phenotype. An active IL-6R/STAT3/miR-34a loop was necessary for EMT, invasion, and metastasis of CRC cell lines and was associated with nodal and distant metastasis in CRC patient samples. p53 activation in CRC cells interfered with IL-6–induced invasion and migration via miR-34a–dependent downregulation of IL6R expression. In Mir34a-deficient mice, colitis-associated intestinal tumors displayed upregulation of p-STAT3, IL-6R, and SNAIL and progressed to invasive carcinomas, which was not observed in WT animals. Collectively, our data indicate that p53-dependent expression of miR-34a suppresses tumor progression by inhibiting a IL-6R/STAT3/miR-34a feedback loop.

Authors

Matjaz Rokavec, Meryem Gülfem Öner, Huihui Li, Rene Jackstadt, Longchang Jiang, Dmitri Lodygin, Markus Kaller, David Horst, Paul K. Ziegler, Sarah Schwitalla, Julia Slotta-Huspenina, Franz G. Bader, Florian R. Greten, Heiko Hermeking

×

Abstract

The metastatic spread of tumor epithelial cells accounts for over 90% of cancer-specific mortality; however, the molecular mechanisms that govern tumor spread and distant recolonization remain unclear. In this issue of JCI, Rokavec and colleagues shine light on this murky aspect of tumor biology by focusing through the lens of microenvironmental contributions, namely inflammation, as driving signals that set off a delicate, intracellular feedback loop among cytokine receptors, transcription factors and miRNAs. This study provides in vivo evidence and identifies molecular players behind the elusive switch that drives the epithelial-to-mesenchymal transition and the mesenchymal-to-epithelial transition.

EMT/MET switch

The migratory capacity conferred on cells following the epithelial-to-mesenchymal transition (EMT) is a developmental necessity that has become a predominant hypothesis to explain epithelial cancer metastases and therapeutic resistance (1). In the simplest terms, selective pressures (e.g., nutrient deprivation, hypoxia, therapeutics, etc.) on epithelial tumor cells activate dormant signaling pathways that allow these tumor cells to lose epithelial characteristics and take on mesenchymal properties, including migration and invasion that are advantageous for tumor survival. The concept that EMT promotes cancer metastasis is supported by the reality that mesenchymal tumors, such as sarcomas, are some of the most difficult tumors to treat. However, if mesenchymal properties are so advantageous for cancer spread, why then do most metastatic lesions display epithelial properties similar to those of the primary tumor?

A predominant answer to this question resides in the mesenchymal-to-epithelial transition (MET), which would allow transformed mesenchymal-like cells to regain their epithelial characteristics, a state that is perhaps more advantageous for survival in a foreign microenvironment. As obvious as this explanation appears to be, there are many unanswered questions that remain. For instance, there is a lack of solid in vivo evidence to support the induction of MET following metastasis. Furthermore, if MET does occur, what are the molecular pathways involved in promoting tumor aggressiveness (EMT), and how can these pathways be dialed back enough to reestablish epithelial characteristics? Furthermore, what are the unique aspects of the primary and distant microenvironments that provide the necessary stimuli to initiate the switch between EMT and MET?

Primary and distant tumor microenvironments

Tumor epithelia cells exist within a complex amalgam of fibroblasts, immune cells, nervous cells, vasculature, musculature, soluble signaling molecules, and extracellular matrices commonly referred to as the microenvironment (2). This microenvironment is dynamic and coevolves with the tumor cells to inhibit or further enhance progression depending on its specific components (Figure 1). The primary microenvironment is associated with acute inflammation in response to the presence of the tumor and disruptions in the basement membrane. This inflammation is orchestrated by a complex symphony of cytokine and chemokine signaling molecules. Of these, a highly studied chemokine, IL-6, is secreted by and acts on many cells within the microenvironment and seems to universally promote inflammatory and tumor progression as well as EMT (3, 4). Furthermore, high levels of serum IL-6 have been correlated with poor survival outcomes. While the local inflammation is critical for tumor development and progression, the role of localized inflammation in the recolonization of tumor cells in a distant microenvironment is still being investigated.

The IL-6/STAT3/miR-34a feedback loop is a molecular switch that controls EMFigure 1

The IL-6/STAT3/miR-34a feedback loop is a molecular switch that controls EMT/MET transition. The complex milieu of primary colorectal cancer is mainly characterized by the presence of tumor epithelial cells, cancer-associated fibroblasts (CAF), vasculature, and cells of the immune system that interact and support each other in promoting tumor growth and local invasion. The inflammatory microenvironment, through its major mediator IL-6, triggers the activation of the IL-6R–mediated IL-6/STAT3 pathway, which represses the expression of miR-34a, thus inhibiting the miR-34a–mediated suppression of SNAIL. Therefore, the activation of the loop by IL-6–induced EMT, through its downstream effector SNAIL, shifts the cellular phenotype toward a mesenchymal state that is advantageous for the invasion, intravasation, and extravasation steps of the metastatic cascade. Conversely, the inactivation of this loop at the site of the metastatic colonization (i.e., lungs) aids in switching back to an epithelial state, namely MET, allowing for the outgrowth of metastatic nodules.

Suppression of miR-34a is required for IL-6–driven EMT

In this issue of the JCI, Rokavec et al. (5) report that they examined the mechanism of the EMT/MET switch, identified an IL-6–driven feedback loop that allows for the induction of EMT, and determined that removal of IL-6 signaling subsequently reverses the effects of this feedback loop. Mutations in the gene encoding the tumor suppressor p53 that result in loss of function are the most common mutations in adult solid tumors (6). The expression of the miR-34 family of microRNAs is induced by p53, and the loss of miR-34a expression has been correlated with EMT through the induction of the EMT transcription factor SNAIL (7). Here, the authors show that IL-6 signaling, through its receptor IL-6R, activates STAT3, which directly represses MIR34A gene expression. Furthermore, repression of miR-34a was required for IL-6–mediated EMT, as miR-34a silences IL-6R (Figure 1). Finally, expression of this IL-6/STAT3/miR-34a feedback loop was discovered in primary colorectal tumors and associated with the presence of distant metastasis in patients.

The key experiment by Rokavec and colleagues (5) demonstrated that both IL-6 treatment and loss of miR-34a result in increased lung metastasis in a tail-vein injection model of colorectal cancer compared with controls. Conceptually, if MET was not necessary for tumor formation at distal sites, then expression of miR-34a should remain low in the metastatic lesions; however, Rokavec et al. (5) demonstrated that expression of miR-34a and other EMT markers was similar to non–IL-6–treated cells. These results suggest that activation of the IL-6R/STAT3/miR-34a loop by IL-6–induced EMT shifts tumor cells toward a mesenchymal state that is advantageous for invasion, intravasation, and extravasation steps of the metastatic cascade. On the contrary, inactivation or disruption of the IL-6R/STAT3/miR-34a loop, perhaps by the reduction of IL-6 in a new microenvironment, induces MET and allows cells to switch back to an epithelial state. This shift could be important to facilitating colonization and outgrowth. Therefore, Rokavec and colleagues (5) have not only provided in vivo evidence for MET, but have also linked specific tumor microenvironments to activation and repression of a signaling loop that could explain the balance between EMT and MET.

Is MET real in patients?

As important as these findings are, many questions remain unanswered and need to be addressed in order to solidify the existence of MET in patients. For instance, the murine tail-vein injection model of colorectal cancer does not take into account the systemic effects of inflammation developed in response to the presence of a primary tumor. Specifically, the amount of IL-6 in the primary microenvironment versus the distant microenvironment may not be different, especially considering that elevated IL-6 in patient serum is often reported. Clinically, if IL-6 expression were elevated in the lung, would the size or epithelial characteristics of the metastases actually be decreased? Additionally, would not the presence of metastatic nodules also promote local inflammation and therefore start EMT all over again? Would this feedback loop be required or present if p53 function/miR34-a expression were completely ablated?

Most importantly, the implications for patient treatment still need to be determined. The association between inflammation and poor prognosis has already been established. Could the knowledge of this, and yet-to-be-determined molecular switches, be useful in developing treatments that could prevent the metastatic spread of tumor cells? These are difficult questions to answer due to the complex nature of the local and distant tumor microenvironments. However, now that a specific signaling pathway has been identified, autochthonous or syngeneic mouse models should be examined to determine the therapeutic utility of this pathway.

Acknowledgments

The authors would like to acknowledge their funding support, provided by NIH grants CA125550, CA155370, CA151925, DK081576, DK055001, and CA16672; the Metastasis Research Center at the MD Anderson Cancer Center; and the Cancer Prevention and Research Institute of Texas.

Address correspondence to: Raghu Kalluri, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77054, USA. Phone: 713.792.8733; Fax: 713.792.9636; E-mail: rkalluri@mdanderson.org.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J Clin Invest. 2014;124(4):1458–1460. doi:10.1172/JCI75239.

See the related article at IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.

References
  1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
    View this article via: JCI PubMed CrossRef Google Scholar
  2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.
    View this article via: PubMed CrossRef Google Scholar
  3. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(suppl 1):i104–i108.
    View this article via: PubMed CrossRef Google Scholar
  4. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1(6–7):303–314.
    View this article via: PubMed CrossRef Google Scholar
  5. Rokavec M, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124(4):1853–1867.
    View this article via: JCI Google Scholar
  6. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8.
    View this article via: PubMed CrossRef Google Scholar
  7. Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007;12(5):414–418.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (March 18, 2014): No description
  • Version 2 (April 1, 2014): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • EMT/MET switch
  • Primary and distant tumor microenvironments
  • Suppression of miR-34a is required for IL-6–driven EMT
  • Is MET real in patients?
  • Acknowledgments
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts